Fairbanks, October 6, 2023 - Foundation Health Partners (FHP) is excited to share an important update with our community: Nirsevimab, an innovative preventive measure against the respiratory syncytial virus (RSV), became available nationwide on October 1, 2023. This significant development offers a unique approach to safeguarding children from RSV. 

Last year, Fairbanks Memorial Hospital (FMH) admitted numerous children due to RSV-related illnesses, and even more were seen in the Emergency Department. By having Nirsevimab as a prevention tool in Interior Alaska, we will significantly reduce this number to ensure healthier childhoods. 

What is RSV? 

Respiratory Syncytial Virus (RSV) is a common respiratory infection that can have severe consequences for newborns and young children. It often leads to bronchiolitis (inflammation of the small airways in the lungs) or pneumonia (lung infection). While most children recover from RSV with mild symptoms, some, especially those born prematurely or with underlying health conditions, may experience severe illness. 

Understanding Nirsevimab: An Extra Layer of Protection 

Nirsevimab introduces a new standard in protecting infants and young children from severe RSV disease. This medication harnesses the power of monoclonal antibodies by binding to the RSV virus and neutralizing it before it can make children sick. These antibodies help fend off the virus, preventing severe illness. It is important to note that Nirsevimab is not a treatment for children already infected with RSV. 

Dr. Laura Brunner, FMH neonatal Intensive Care Unit and Inpatient Pediatrics Medical Director, expressed her enthusiasm for this groundbreaking approach, stating, “It is really exciting to have another tool available to help protect young children.” 

Who Should Receive Nirsevimab? 

Nirsevimab antibody immunization is recommended for all infants under 8 months of age, especially those born during or entering their first RSV season. A dose of RSV antibody is also recommended for some children aged 8 to 19 months who are entering their second RSV season and meet specific higher-risk criteria. 

Nurse Practitioner Jeri Rosenbloom, an inpatient pediatric provider at FHP, underscores the significance of timing for Nirsevimab administration, “All newborns are recommended to get this medication in the first week of life during RSV season. In Alaska, this is typically from October to March.  If your child is younger than 8 months old and has not received this medication at the start of RSV season, they can receive this medication in an outpatient setting. If your child is 8 months or older, talk with your pediatric provider to see if this medication is right for your child.” 

Tanana Valley Clinic (TVC) also plans to administer this medication in an outpatient setting to young children as supply allows.  Dr. Celina Clift, TVC Pediatrics Medical Director, shares the enthusiasm for this medication, saying, “This is a historic moment in pediatric medicine.” 

Powerful Protection That Lasts 

Nirsevimab delivers robust protection and is anticipated to provide protection for at least 5 months, which is roughly the duration of an RSV season. This level of defense is estimated to lower the risk of severe RSV disease by an impressive 80%, representing a significant advancement in pediatric healthcare. 

This nationwide rollout marks a groundbreaking step toward enhancing child well-being, highlighting its potential to make a profound impact on the lives of countless children across the country. With Nirsevimab, we are looking forward to a new era of RSV protection for our youngest community members. 

Sources:  

CDC. Learn about RSV in Infants and Young Children. Centers for Disease Control and Prevention. Retrieved from: https://www.cdc.gov/rsv/high-risk/infants-young-children.html?fbclid=IwAR0OrRQwhBYqWpsYS8KxIXt7nKGMBpUdcJuaBbO4zfc71ciU96p1Wlje1h4  

 American Academy of Pediatrics. Nirsevimab Frequently Asked Questions. Retrieved from: https://www.aap.org/en/patient-care/respiratory-syncytial-virus-rsv-prevention/nirsevimab-frequently-asked-questions/#:~:text=Nirsevimab%20provides%20at%20least%205